February 26, 2018 / 7:18 AM / in 8 months

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

Feb 26(Reuters) - Sumitomo Dainippon Pharma Co Ltd

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

Source text in Japanese:goo.gl/akBwrg

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below